Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 2/20 | 0.55 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14233914 | 0.88 | KAT6A (0.58) | KAT6APARP1SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL9713054 | 0.87 | SMN1; SMN2 (0.67) | PARP1SMN1; SMN2KMT2AL3MBTL1HDAC3 | |
| SCHEMBL13761327 | 0.86 | PARP1 (0.51) | PARP1SMN1; SMN2KMT2AL3MBTL1GAA | |
| SCHEMBL2542308 | 0.86 | PARP1 (0.51) | PARP1SMN1; SMN2KMT2AL3MBTL1GAA | |
| SCHEMBL27272636 | 0.86 | SMN1; SMN2 (0.54) | PARP1SMN1; SMN2KMT2AL3MBTL1GAA | |
| SCHEMBL16248158 | 0.86 | L3MBTL1 (0.69) | KAT6ASMYD3SMN1; SMN2L3MBTL1HDAC3 | |
| SCHEMBL14081049 | 0.86 | LOXL2 (0.61) | PARP1SMN1; SMN2KMT2AL3MBTL1GAA | |
| SCHEMBL17033979 | 0.86 | PARP1 (0.51) | PARP1SMN1; SMN2KMT2AL3MBTL1GAA | |
| SCHEMBL21872371 | 0.86 | L3MBTL1 (0.51) | PARP1SMN1; SMN2KMT2AL3MBTL1GAA | |
| SCHEMBL17790216 | 0.85 | PARP1 (0.53) | PARP1SMN1; SMN2GAAHSD17B10MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023093787-A1 | BENZODIAZEPINE COMPOUND AND APPLICATION THEREOF AS RHO KINASE INHIBITOR | 成都奥睿药业有限公司 | 2023-06-01 | — | — | WO | disclosed |
| US-10357477-B2 | Anticancer compounds | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2019-07-23 | — | — | US | disclosed |
| US-20180071258-A1 | ANTICANCER COMPOUNDS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2018-03-15 | — | — | US | disclosed |
| US-9745313-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-29 | — | — | US | disclosed |
| US-20170152287-A1 | METHODS AND COMPOSITIONS FOR SITE-SPECIFIC LABELING OF PEPTIDES AND PROTEINS | UNIVERSITY OF ROCHESTER | 2017-06-01 | — | — | US | disclosed |
| US-9557336-B2 | Methods and compositions for site-specific labeling of peptides and proteins | UNIVERSITY OF ROCHESTER (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160362414-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-15 | — | — | US | disclosed |
| US-9453029-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160263234-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. | 2016-09-15 | — | — | US | disclosed |
| US-9315542-B2 | Prodrugs of peptide epoxy ketone protease inhibitors | ONYX THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-8828983-B2 | Macrocycles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-09 | — | — | US | disclosed |
| WO-2014039715-A1 | METHODS AND COMPOSITIONS FOR SITE-SPECIFIC LABELING OF PEPTIDES AND PROTEINS | UNIVERSITY OF ROCHESTER (US) | 2014-03-13 | — | — | WO | disclosed |
| WO-2014011695-A2 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | ONYX THERAPEUTICS, INC. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7576117-B1 | Cyclic amine CCR3 antagonist | TEIJIN LIMITED (JP) | 2009-08-18 | — | — | US | disclosed |
| US-7420066-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| EP-0471756-A4 | SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF | — | 1992-04-08 | — | — | EP | disclosed |
| EP-0471756-A1 | SACCHARIN DERIVATIVES USEFUL AS PROTEOLYTIC ENZYME INHIBITORS AND PREPARATION THEREOF. | STERLING WINTHROP INC (US) | 1992-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152287-A1 | METHODS AND COMPOSITIONS FOR SITE-SPECIFIC LABELING OF PEPTIDES AND PROTEINS | PTMS, ACP1, QPCTL | KAT6A 2824/4885SMYD3 2938/4885PARP1 4650/4885 |
| US-20180071258-A1 | ANTICANCER COMPOUNDS | RB1, MCL1, TP53 | KAT6A 2919/4885SMYD3 1515/4885PARP1 367/4885 |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | KAT6A 23/4885SMYD3 1839/4885PARP1 499/4885 |
| US-20160263234-A1 | PRODRUGS OF PEPTIDE EPOXY KETONE PROTEASE INHIBITORS | PREP, VIP, PEPD | KAT6A 2599/4885SMYD3 3715/4885PARP1 3161/4885 |
| US-20160362414-A1 | MACROCYCLES AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F11 | KAT6A 3581/4885SMYD3 4006/4885PARP1 1720/4885 |
| US-10357477-B2 | Anticancer compounds | RB1, MCL1, TP53 | KAT6A 2919/4885SMYD3 1515/4885PARP1 367/4885 |
| US-20110288117-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | KAT6A 21/4885SMYD3 2177/4885PARP1 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.